EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Microbial aldehyde-alcohol dehydrogenase degrades metformin to limit therapeutic response in type 2 diabetes

Yue Zhao, Chen Peng, Ying Xia, Tiejun Dong, Juan Xu, Xiaodong Shan, Xiang Zhong, Jingchuan Xue, Ziqian Bing, Pengfei Li, Jingyu Han, Yunzhong Nie und 3 weitere

Cell Metabolism · 2026-11 · 38 (11) · 2320-2337.e15

DOI: 10.1016/j.cmet.2026.09.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2026-11. Verfasst von Yue Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Department of Endocrinology, Endocri…. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Alcohol Dehydrogenase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing University, National Natural Science Foundation of China, Innovative Research Team of High-level Local Universities in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin is a first-line therapy for type 2 diabetes, yet therapeutic responses vary widely. Whether gut microbes directly inactivate metformin and limit its efficacy remains unclear. Here, we identify a gut microbial aldehyde-alcohol dehydrogenase, AdhE, from Eubacterium species enriched in individuals with a low response to metformin. AdhE converts metformin to pharmacologically inactive products, lowering intestinal and systemic drug exposure. Genetic deletion of AdhE or phage-mediated depletion of AdhE-producing Eubacterium hallii MD1 restores metformin exposure and glycemic control in mice. An artificial intelligence-guided structure-based screen identifies the dietary phytochemical daidzein as a microbial AdhE inhibitor that blocks metformin degradation and improves metformin responsiveness. These findings establish gut microbial drug inactivation as a modifiable determinant of therapeutic response and provide a framework for microbial enzyme-guided strategies to improve established therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Hypoglycemic AgentsAlcohol DehydrogenaseAnimalsHumansMiceIsoflavonesMice, Inbred C57BLGastrointestinal Microbiome

Stichwörter der Autor:innen

gut microbiotametformin degradationmetformin-response heterogeneitymicrobial drug metabolismmicrobial enzyme AdhEstructural enzymologytype 2 diabetes

Substanzen

MetforminHypoglycemic AgentsdaidzeinAlcohol DehydrogenaseIsoflavones

Autor:innen und Institutionen

  • The State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital,…
  • Shanghai Institute of Precision Medicine and Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 115 Jinzun Road, Shanghai 200125, China.
  • Jiangsu Key Laboratory of Molecular Medicine, Division of Immunology, Medical School, Nanjing University, Nanjing 210000, China.
  • Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing University, Nanjing 210000, China.
  • Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China.
  • Guangdong Basic Research Center of Excellence for Ecological Security and Green Development, Key Laboratory for City Cluster Environmental Safety and Green Development of the Ministry of Education, School of Ecology, En…

Förderung

  • Nanjing University
  • National Natural Science Foundation of China
  • Innovative Research Team of High-level Local Universities in Shanghai
  • Shanghai Jiao Tong University School of Medicine

Zitieren

APA

Zhao, Y., Peng, C., Xia, Y., Dong, T., Xu, J., Shan, X., Zhong, X., Xue, J., Bing, Z., Li, P., Han, J., Nie, Y., He, K., Cao, Y., & Wang, T. (2026). Microbial aldehyde-alcohol dehydrogenase degrades metformin to limit therapeutic response in type 2 diabetes. Cell Metabolism, 38(11), 2320-2337.e15. https://doi.org/10.1016/j.cmet.2026.09.003

Vancouver

Zhao Y, Peng C, Xia Y, Dong T, Xu J, Shan X, et al. Microbial aldehyde-alcohol dehydrogenase degrades metformin to limit therapeutic response in type 2 diabetes. Cell Metabolism. 2026;38(11):2320-2337.e15. doi:10.1016/j.cmet.2026.09.003

BibTeX
@article{Zhao2026,
  author = {Zhao, Yue and Peng, Chen and Xia, Ying and Dong, Tiejun and Xu, Juan and Shan, Xiaodong and Zhong, Xiang and Xue, Jingchuan and Bing, Ziqian and Li, Pengfei and Han, Jingyu and Nie, Yunzhong and He, Kelei and Cao, Yu and Wang, Tingting},
  title = {Microbial aldehyde-alcohol dehydrogenase degrades metformin to limit therapeutic response in type 2 diabetes},
  journal = {Cell Metabolism},
  year = {2026},
  volume = {38},
  number = {11},
  pages = {2320--2337.e15},
  doi = {10.1016/j.cmet.2026.09.003}
}
Kostenlos starten →